

Supplementary Table 1

n=	CR	PR	Author, Year
11 ^{/17}	0	1	Chakraborty et al. 1998
16	2	3	Nestle et al. 1998, Gilliet et al. 2003
11	0	0	Thurner et al. 1999
13 ^{/14}	0	1	Mackensen et al. 2000
7	0	1	Panelli et al. 2000
8 ^{/12}	0	0	Schuler-Thurner et al. 2000
17 ^{/18}	3	4	Banchereau et al. 2001, Palucka et al. 2003, Fay et al. 2006
8	0	0	Jonuleit et al. 2001
16	1	0	Lau et al. 2001
11 ^{/17}	0	1	Chang et al. 2002
17	0	1	Krause et al. 2002
22	1	0	Schuler-Thurner et al. 2002
26 ^{/27}	0	0	Bedrosian et al. 2003
10 ^{/18}	1	0	Butterfield et al. 2003
17 ^{/19}	0	1	de Vries et al. 2003
10	0	0	Nagayama et al. 2003
17	3	3	O'Rourke et al. 2003
13	0	1	Slingluff et al. 2003
22	1	2	Smithers et al. 2003
11 ^{/13}	0	0	Barbuto et al. 2004
54	0	0	Dillman et al. 2004, 2009 & 2012
6	0	1	Di Nicola et al. 2004
4 ^{/6}	1	1	Griffioen et al. 2004
11	0	0	Haenssle et al. 2004
33	0	3	Hersey et al. 2004
4 ^{/10}	1	0	Ribas et al. 2004
17 ^{/20}	1	0	Trefzer et al. 2004
11	0	1	Vilella et al. 2004
9	1	1	Akiyama et al. 2005
19 ^{/22}	0	0	Banchereau et al. 2005
19 ^{/20}	0	0	Escobar et al. 2005
15	0	1	Escudier et al. 2005
12	0	2	Linette et al. 2005
0 ^{/6}	/	/	Davis et al. 2006
6	0	1	Grover et al. 2006
20 ^{/22}	0	0	Kyte et al. 2006a
14	0	0	Lesimple et al. 2006
20	0	0	Nakai et al. 2006, Nakai et al. 2008
20 ^{/21}	1	1	Palucka et al. 2006
27	2	6	Ridolfi et al. 2006, 2010 & 2011
15	1	0	Salcedo et al. 2006
41 ^{/47}	0	2	Schadendorf et al. 2006
5 ^{/8}	0	0	Trakatelli et al. 2006

Supplementary Table 1a: Objective responses to DC vaccination in melanoma (cont'd on next page)

n=	CR	PR	Author, Year
3 ^{/13}	0	0	Tuettenberg et al. 2006
10	0	1	Wei et al. 2006
46	3	3	O'Rourke et al. 2007
40	0	0	Bercovici et al. 2008
34	0	3	Hersey et al. 2008
22	0	0	Redman et al. 2008
16	0	0	von Euw et al. 2008
9	0	1	Chang et al. 2009
0 ^{/50}	/	/	Lopez et al. 2009
16	2	2	Ribas et al. 2009
30	1	0	Jacobs et al. 2010
33	1	2	Ribas et al. 2010
46	0	0	Trepiakas et al. 2010
5 ^{/6}	0	0	Kim et al. 2011
27	2	0	Lesterhuis et al. 2011
15	2	2	Neyns et al. 2011 & 2012
0 ^{/36}	/	/	Romano et al. 2011
25	0	3	Steele et al. 2011
20 ^{/35*}	1	1	Wilgenhof et al. 2011, Benteyn et al. 2013
28	0	0	Ellebaek et al. 2012
6*	0	3	Neyns et al. 2012
24	0	1	Oshita et al. 2012
29	0	0	Aarntzen et al. 2013
7	1	2	Carreno et al. 2013
2 ^{/12}	1	1	Dannull et al. 2013
17 ^{/20}	0	1	Ridolfi et al. 2013
15	0	0	Tel et al. 2013
15	2	2	Wilgenhof et al. 2013
1205^{/1394}	36	67	= 8.5% OR

n=number of vaccinated patients evaluable for tumour response assessment/total number of patients. CR=complete response as defined by RECIST. PR=partial response as defined by RECIST. *=responses attributed to other treatment modalities used in combination with DC therapy: IFN- α /ipilimumab (Wilgenhof et al. 2011) or ipilimumab (Neyns et al. 2012). OR=proportion of patients achieving an objective response, calculated by dividing the sum of CR and PR by the number of vaccinated patients evaluable for tumour response assessment.
Excludes case reports and articles not written in English. Last update: November 14, 2013.

Supplementary Table 1a: Objective responses to DC vaccination in melanoma

n=	CR	PR	Author, Year
95 ^{/107}	3	25	Murphy et al. 1996, 1999a & 1999b Tjoa et al. 1997, 1998 & 1999
12	0	3	Burch et al. 2000
17	1	3	Murphy et al. 2000
31	0	3	Small et al. 2000
21	0	0	Fong et al. 2001a & 2001b
7 ^{/13}	0	0	Heiser et al. 2002
24	0	0	Barrou et al. 2004
19 ^{/21}	1	0	Burch et al. 2004
11	0	0	Pandha et al. 2004
4 ^{/5}	0	0	Vonderheide et al. 2004
19	0	0	Mu et al. 2005, Kyte et al. 2006b
12 ^{/20}	0	0	Su et al. 2005
8	0	1	Fuessel et al. 2006
0 ^{/14}	/	/	Perambakam et al. 2006 & 2010
21 ^{/22}	0	1	Rini et al. 2006
147	0	5	Small et al. 2006, Higano et al. 2009
12	0	0	Thomas-Kaskell et al. 2006
6	0	0	Waeckerle-Men et al. 2006
12	0	1	Hildenbrand et al. 2007
311 ^{/341}	0	8	Kantoff et al. 2010
14 ^{/20}	0	2	Reyes et al. 2013
803^{/894}	5	52	= 7.1% OR

n=number of vaccinated patients evaluable for tumour response assessment/total number of patients. CR=complete response as defined by RECIST *and/or* a normalization of PSA levels below background. PR=partial response as defined by RECIST *and/or* a $\geq 50\%$ decline of PSA levels. OR=proportion of patients achieving an objective response, calculated by dividing the sum of CR and PR by the number of vaccinated patients evaluable for tumour response assessment.

Excludes case reports and articles not written in English. Last update: November 14, 2013.

Supplementary Table 1b: Objective responses to DC vaccination in prostate cancer

n=	CR	PR	Author, Year
8	0	0	Kikuchi et al. 2001
0 ⁹	/	/	Yu et al. 2001
10	0	0	Yamanaka et al. 2003
7	0	1	Caruso et al. 2004
15	0	4	Kikuchi et al. 2004
0 ¹⁹	/	/	Niu et al. 2004
6 ¹²	0	1	Rutkowski et al. 2004
0 ¹⁴	/	/	Yu et al. 2004
13*	0	3	Wheeler et al. 2004
12	0	1	Liau et al. 2005
24	0	1	Yamanaka et al. 2005
0 ⁵⁶	/	/	De Vleeschouwer et al. 2008
32 ^{34*}	0	4	Wheeler et al. 2008
0 ¹²	/	/	Sampson et al. 2009
0 ⁸	/	/	Ardon et al. 2010a
0 ⁴⁵	/	/	Ardon et al. 2010b
0 ¹⁷	NE	NE	Chang et al. 2011
0 ¹⁰	/	/	Fadul et al. 2011
22	0	2	Okada et al. 2011
0 ³⁴	/	/	Prins et al. 2011 & 2013, Fong et al. 2012
9	0	0	Akiyama et al. 2012
0 ⁷⁷	/	/	Ardon et al. 2012
0 ¹⁸	/	/	Cho et al. 2012
13*	3	6	Jie et al. 2012
0 ⁵	/	/	Valle et al. 2012
2	0	0	Kamigaki et al. 2013
0 ^{3*}	0	1	Lasky et al. 2013
0 ¹⁵	/	/	Pellegatta et al. 2013
0 ²⁰	/	/	Phuphanich et al. 2013
0 ⁷	NE	NE	Vik-Mo et al. 2013
173⁵⁵⁰	3	24	= 15.6% OR

n=number of vaccinated patients evaluable for tumour response assessment/total number of patients. CR=complete response based on radiological findings. PR=partial response (≥50% decrease in tumour size) based on radiological findings. NE=not evaluable (% response not specified). *=responses attributed to other treatment modalities used in combination with DC therapy: chemotherapy (Wheeler et al. 2004, Wheeler et al. 2008; Jie et al. 2012) or chemotherapy + radiation therapy (Lasky et al. 2013). OR=proportion of patients achieving an objective response, calculated by dividing the sum of CR and PR by the number of vaccinated patients evaluable for tumour response assessment.

Excludes case reports and articles not written in English. Last update: November 14, 2013.

Supplementary Table 1c: Objective responses to DC vaccination in primary brain tumors (glioma)

n=	CR	PR	Author, Year
4	0	1	Holti et al. 1999
3	0	0	Azuma et al. 2002
27 ^{/35}	2	1	Holti et al. 2002
30 ^{/37}	0	1	Marten et al. 2002, 2003 & 2006, Kraemer et al. 2010
12	0	0	Oosterwijk-Wakka et al. 2002
12 ^{/14}	0	1	Gitlitz et al. 2003
2 ^{/10}	0	0	Su et al. 2003
13 ^{/26}	0	0	Avigan et al. 2004
5	0	0	Arroyo et al. 2004
19 ^{/22}	1	2	Barbuto et al. 2004
5	0	0	Pandha et al. 2004
0 ^{/10}	/	/	Dannull et al. 2005
22	0	0	Holti et al. 2005
20	1	2	Wierecky et al. 2006
6 ^{/8}	0	0	Bleumer et al. 2007
9	0	1	Kim et al. 2007
3	0	0	Matsumoto et al. 2007
10	0	1	Wei et al. 2007
27 ^{/30}	0	0	Berntsen et al. 2008
4 ^{/5}	0	0	Lemoine et al. 2009
18*	3	6	Schwaab et al. 2009
6	0	0	Baek et al. 2011
21*	0	9	Amin et al. 2013
7	0	0	Florcken et al. 2013
2	0	1	Kamigaki et al. 2013
287^{/344}	7	26	= 11.5% OR

n=number of vaccinated patients evaluable for tumour response assessment/total number of patients. CR=complete response as defined by RECIST. PR=partial response as defined by RECIST. *=responses attributed to other treatment modalities used in combination with DC therapy: IL-2/IFN- α (Schwaab et al. 2009) or sunitinib (Amin et al. 2013). OR=proportion of patients achieving an objective response, calculated by dividing the sum of CR and PR by the number of vaccinated patients evaluable for tumour response assessment.
Excludes case reports and articles not written in English. Last update: November 14, 2013.

Supplementary Table 1d: Objective responses to DC vaccination in renal cell cancer

Full reference list for Supplementary Table 1

- Aarntzen EH, De Vries IJ, Lesterhuis WJ, et al. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. *Cancer Res* 2013; **73**: 19-29.
- Akiyama Y, Tanosaki R, Inoue N, et al. Clinical response in Japanese metastatic melanoma patients treated with peptide cocktail-pulsed dendritic cells. *J Transl Med* 2005; **3**: 4.
- Akiyama Y, Oshita C, Kume A, et al. alpha-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial. *BMC Cancer* 2012; **12**: 623.
- Amin A, Dudek A, Logan T, et al. Prolonged survival with personalized immunotherapy (AGS-003) in combination with sunitinib in unfavorable risk metastatic RCC (mRCC). *J Clin Oncol* 2013; **31**: 357.
- Ardon H, Van Gool S, Lopes IS, et al. Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study. *J Neurooncol* 2010; **99**: 261-72.
- Ardon H, De Vleeschouwer S, Van Calenbergh F, et al. Adjuvant dendritic cell-based tumourvaccination for children with malignant brain tumours. *Pediatr Blood Cancer* 2010; **54**: 519-25.
- Ardon H, Van Gool SW, Verschuere T, et al. Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial. *Cancer Immunol Immunother* 2012; **61**: 2033-44.
- Arroyo JC, Gabilondo F, Llorente L, Meraz-Rios MA, Sanchez-Torres C. Immune response induced in vitro by CD16(-) and CD16(+) monocyte-derived dendritic cells in patients with metastatic renal cell carcinoma treated with dendritic cell vaccines. *J Clin Immunol* 2004; **24**: 86-96.
- Avigan D, Vasir B, Gong JL, et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. *Clin Cancer Res* 2004; **10**: 4699-708.
- Azuma T, Horie S, Tomita K, et al. Dendritic cell immunotherapy for patients with metastatic renal cell carcinoma: University of Tokyo experience. *Int J Urol* 2002; **9**: 340-6.
- Baek S, Kim CS, Kim SB, et al. Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial. *J Transl Med* 2011; **9**: 178.
- Banchereau J, Palucka AK, Dhodapkar M, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. *Cancer Res* 2001; **61**: 6451-58.
- Banchereau J, Ueno H, Dhodapkar M, et al. Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34(+) progenitors and activated with type I interferon. *J Immunother* 2005; **28**: 505-16.
- Barbuto JAM, Ensina LFC, Neves AR, et al. Dendritic cell-tumor cell hybrid vaccination for metastatic cancer. *Cancer Immunol Immunother* 2004; **53**: 1111-18.
- Barrou B, Benoit GR, Ouldakci M, et al. Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA. *Cancer Immunol Immunother* 2004; **53**: 453-60.
- Bedrosian I, Mick R, Xu SW, et al. Intranasal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. *J Clin Oncol* 2003; **21**: 3826-35.
- Benteyn D, Van Nuffel AMT, Wilgenhof S, et al. Characterization of CD8(+) T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL). *Biomed Res Int* 2013; **2013**: 976383.
- Bercovici N, Haicheur N, Massicard S, et al. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients. *J Immunother* 2008; **31**: 101-12.
- Berntsen A, Trepiakas R, Wenandy L, et al. Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma - A clinical, phase 1/2 trial. *J Immunother* 2008; **31**: 771-80.
- Bleumer I, Tiemessen DM, Oosterwijk-Wakka JC, et al. Preliminary analysis of patients with progressive renal cell carcinoma vaccinated with CA9-peptide-pulsed mature dendritic cells. *J Immunother* 2007; **30**: 116-22.
- Burch PA, Breen JK, Buckner JC, et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. *Clin Cancer Res* 2000; **6**: 2175-82.
- Burch PA, Croghan GA, Gastineau DA, et al. Immunotherapy (APC8015, Provenge(R)) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: A phase 2 trial. *Prostate* 2004; **60**: 197-204.
- Butterfield LH, Ribas A, Dissette VB, et al. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. *Clin Cancer Res* 2003; **9**: 998-1008.
- Carreno BM, Becker-Hapak M, Huang A, et al. IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity. *J Clin Invest* 2013; **123**: 3383-94.
- Caruso DA, Orme LM, Neale AM, et al. Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. *Neuro-Oncol* 2004; **6**: 236-46.
- Chakraborty NG, Sporn JR, Tortora AF, et al. Immunization with a tumor-cell-lysate-loaded autologous-antigen-presenting-cell-based vaccine in melanoma. *Cancer Immunol Immunother* 1998; **47**: 58-64.
- Chang AE, Redman BG, Whitfield JR, et al. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. *Clin Cancer Res* 2002; **8**: 1021-32.
- Chang JW, Hsieh JJ, Shen YC, et al. Immunotherapy with dendritic cells pulsed by autologous dactinomycin-induced melanoma apoptotic bodies for patients with malignant melanoma. *Melanoma Res* 2009; **19**: 309-15.
- Chang CN, Huang YC, Yang DM, et al. A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma. *J Clin Neurosci* 2011; **18**: 1048-54.
- Cho DY, Yang WK, Lee HC, et al. Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial. *World Neurosurg* 2012; **77**: 736-44.
- Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. *J Clin Invest* 2005; **115**: 3623-33.

- Dannull J, Haley NR, Archer G, et al. Melanoma immunotherapy using mature DCs expressing the constitutive proteasome. *J Clin Invest* 2013; **123**: 3135-45.
- Davis ID, Chen Q, Morris L, et al. Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8(+) T cells efficiently in cancer patients. *J Immunother* 2006; **29**: 499-511.
- De Vleeschouwer S, Fieuws S, Rutkowski S, et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. *Clin Cancer Res* 2008; **14**: 3098-104.
- de Vries IJM, Lesterhuis WJ, Scharenborg NM, et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. *Clin Cancer Res* 2003; **9**: 5091-100.
- Di Nicola M, Carlo-Stella C, Mortarini R, et al. Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: A phase I trial in metastatic melanoma. *Clin Cancer Res* 2004; **10**: 5381-90.
- Dillman R, Selvan S, Schiltz P, et al. Phase I/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: Planned interim analysis. *Cancer Biother Radiopharm* 2004; **19**: 658-65.
- Dillman RO, Selvan SR, Schiltz PM, et al. Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report. *Cancer Biother Radiopharm* 2009; **24**: 311-9.
- Dillman RO, Cornforth AN, Depriest C, et al. Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma. *J Immunother* 2012; **35**: 641-9.
- Ellebaek E, Engell-Noerregaard L, Iversen TZ, et al. Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial. *Cancer Immunol Immunother* 2012; **61**: 1791-804.
- Escobar A, Lopez M, Serrano A, et al. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients. *Clin Exp Immunol* 2005; **142**: 555-68.
- Escudier B, Dorval T, Chaput N, et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of the first phase I clinical trial. *J Transl Med* 2005; **3**: 10.
- Fadul CE, Fisher JL, Hampton TH, et al. Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. *J Immunother* 2011; **34**: 382-89.
- Fay JW, Palucka AK, Paczesny S, et al. Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells. *Cancer Immunol Immunother* 2006; **55**: 1209-18.
- Florcken A, Kopp J, van Lessen A, et al. Allogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer: A clinical phase I/II study. *Hum Vaccin Immunother* 2013; **9**: 1217-27.
- Fong L, Brockstedt D, Benike C, Wu L, Engleman EG. Dendritic cells injected via different routes induce immunity in cancer patients. *J Immunol* 2001; **166**: 4254-59.
- Fong L, Brockstedt D, Benike C, et al. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. *J Immunol* 2001; **167**: 7150-56.
- Fong B, Jin R, Wang XY, et al. Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM Patients. *PLoS ONE* 2012; **7**: e32614.
- Fuessel S, Meye A, Schmitz M, et al. Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: Results of a Phase I clinical trial. *Prostate* 2006; **66**: 811-21.
- Gilliet M, Kleinhans M, Lantelme E, Schadendorf D, Burg G, Nestle FO. Intranodal injection of semimature monocyte-derived dendritic cells induces T helper type 1 responses to protein neoantigen. *Blood* 2003; **102**: 36-42.
- Gitlitz BJ, Beldegrun AS, Zisman A, et al. A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma. *J Immunother* 2003; **26**: 412-19.
- Griffioen M, Borghi M, Schrier PI, Osanto S, Schadendorf D. Analysis of T-cell responses in metastatic melanoma patients vaccinated with dendritic cells pulsed with tumor lysates. *Cancer Immunol Immunother* 2004; **53**: 715-22.
- Grover A, Kim GJ, Lizee G, et al. Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes. *Clin Cancer Res* 2006; **12**: 5801-08.
- Haenssle HA, Krause SW, Emmert S, et al. Hybrid cell vaccination in metastatic melanoma - Clinical and immunologic results of a phase I/II study. *J Immunother* 2004; **27**: 147-55.
- Heiser A, Coleman D, Dannull J, et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. *J Clin Invest* 2002; **109**: 409-17.
- Hersey P, Halliday GM, Farrelly ML, DeSilva C, Lett M, Menzies SW. Phase I/II study of treatment with matured dendritic cells with or without low dose IL-2 in patients with disseminated melanoma. *Cancer Immunol Immunother* 2008; **57**: 1039-51.
- Hersey P, Menzies SW, Halliday GM, et al. Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. *Cancer Immunol Immunother* 2004; **53**: 125-34.
- Higano CS, Schellhammer PF, Small EJ, et al. Integrated Data From 2 Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trials of Active Cellular Immunotherapy With Sipuleucel-T in Advanced Prostate Cancer. *Cancer* 2009; **115**: 3670-79.
- Hildenbrand B, Sauer B, Kalis O, et al. Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells - A pilot study. *Prostate* 2007; **67**: 500-08.
- Holtl L, Rieser C, Papesh C, et al. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. *J Urol* 1999; **161**: 777-82.
- Holtl L, Zelle-Rieser C, Gander H, et al. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. *Clin Cancer Res* 2002; **8**: 3369-76.
- Holtl L, Ramoner R, Zelle-Rieser C, et al. Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide. *Cancer Immunol Immunother* 2005; **54**: 663-70.
- Jacobs JF, Punt CJ, Lesterhuis WJ, et al. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients. *Clin Cancer Res* 2010; **16**: 5067-78.

- Jie X, Hua L, Jiang W, Feng F, Feng G, Hua Z. Clinical application of a dendritic cell vaccine raised against heat-shocked glioblastoma. *Cell Biochem Biophys* 2012; **62**: 91-99.
- Jonuleit H, Giesecke-Tuetttenberg A, Tuting T, et al. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. *Int J Cancer* 2001; **93**: 243-51.
- Kamigaki T, Kaneko T, Naitoh K, et al. Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors. *Anticancer Res* 2013; **33**: 2971-6.
- Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. *N Engl J Med* 2010; **363**: 411-22.
- Kikuchi T, Akasaki Y, Irie M, Homma S, Abe T, Ohno T. Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. *Cancer Immunol Immunother* 2001; **50**: 337-44.
- Kikuchi T, Akasaki Y, Abe T, et al. Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. *J Immunother* 2004; **27**: 452-59.
- Kim JH, Lee Y, Bae Y-S, et al. Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma. *Clin Immunol* 2007; **125**: 257-67.
- Kim DS, Kim DH, Goo B, et al. Immunotherapy of malignant melanoma with tumor lysate-pulsed autologous monocyte-derived dendritic cells. *Yonsei Med J* 2011; **52**: 990-8.
- Kraemer M, Hauser S, Schmidt-Wolf IG. Long-term survival of patients with metastatic renal cell carcinoma treated with pulsed dendritic cells. *Anticancer Res* 2010; **30**: 2081-6.
- Krause SW, Neumann T, Soruri A, Mayer S, Peters JH, Andreesen R. The treatment of patients with disseminated malignant melanoma by vaccination with autologous cell hybrids of tumor cells and dendritic cells. *J Immunother* 2002; **25**: 421-28.
- Kyte JA, Mu L, Aamdal S, et al. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. *Cancer Gene Ther* 2006; **13**: 905-18.
- Kyte JA, Gaudernack G. Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells. *Cancer Immunol Immunother* 2006; **55**: 1432-42.
- Lasky JL, Panosyan EH, Plant A, et al. Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas. *Anticancer Res* 2013; **33**: 2047-56.
- Lau R, Wang F, Jeffery G, et al. Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. *J Immunother* 2001; **24**: 66-78.
- Lemoine FM, Cherai M, Giverne C, et al. Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer. *Int J Oncol* 2009; **35**: 569-81.
- Lesimple T, Neidhard E-M, Vignard V, et al. Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients. *Clin Cancer Res* 2006; **12**: 7380-88.
- Lesterhuis WJ, Schreiber G, Scharenborg NM, et al. Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used. *Cancer Immunol Immunother* 2011; **60**: 249-60.
- Liau LM, Prins RM, Kiertscher SM, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. *Clin Cancer Res* 2005; **11**: 5515-25.
- Linette GP, Zhang DS, Hodi FS, et al. Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8(+) immunity. *Clin Cancer Res* 2005; **11**: 7692-99.
- Lopez MN, Pereda C, Segal G, et al. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells. *J Clin Oncol* 2009; **27**: 945-52.
- Mackensen A, Herbst B, Chen JL, et al. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. *Int J Cancer* 2000; **86**: 385-92.
- Marten A, Flieger D, Renoth S, et al. Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial. *Cancer Immunol Immunother* 2002; **51**: 637-44.
- Marten A, Renoth S, Heinicke T, et al. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. *Hum Gene Ther* 2003; **14**: 483-94.
- Marten A, Sievers E, Albers P, et al. Telomerase-pulsed dendritic cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. *Ger Med Sci* 2006; **4**: Doc02.
- Matsumoto A, Haraguchi K, Takahashi T, et al. Immunotherapy against metastatic renal cell carcinoma with mature dendritic cells. *Int J Urol* 2007; **14**: 277-83.
- Mu LJ, Kyte JA, Kvalheim G, et al. Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients. *Br J Cancer* 2005; **93**: 749-56.
- Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. *Prostate* 1996; **29**: 371-80.
- Murphy GP, Tjoa BA, Simmons SJ, et al. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. *Prostate* 1999; **38**: 73-78.
- Murphy GP, Tjoa BA, Simmons SJ, et al. Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment. *Prostate* 1999; **39**: 54-59.
- Murphy GP, Tjoa BA, Simmons SJ, Rogers MK, Kenny GM, Jarisch J. Higher-dose and less frequent dendritic cell infusions with PSMA peptides in hormone-refractory metastatic prostate cancer patients. *Prostate* 2000; **43**: 59-62.
- Nagayama H, Sato K, Morishita M, et al. Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2. *Melanoma Res* 2003; **13**: 521-30.
- Nakai N, Asai J, Ueda E, Takenaka H, Katoh N, Kishimoto S. Vaccination of Japanese patients with advanced melanoma with peptide, tumor lysate or both peptide and tumor lysate-pulsed mature, monocyte-derived dendritic cells. *J Dermatol* 2006; **33**: 462-72.

- Nakai N, Katoh N, Kitagawa T, Ueda E, Takenaka H, Kishimoto S. Evaluation of survival in Japanese stage IV melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cells. *J Dermatol* 2008; **35**: 801-03.
- Nestle FO, Aljagjic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. *Nat Med* 1998; **4**: 328-32.
- Neyns B, Wilgenhof S, Van Nuffel AMT, et al. A phase I clinical trial on the combined intravenous (IV) and intradermal (ID) administration of autologous TriMix-DC cellular therapy in patients with pretreated melanoma (TriMixIDIV). *J Clin Oncol* 2011; **29**: 2519.
- Neyns B, Wilgenhof S, Van Nuffel AMT, et al. Phase IB study on combined intradermal (ID) and intravenous (IV) administration of autologous mRNA electroporated dendritic cells (DC) as a single-agent cellular immunotherapy or combined with ipilimumab. *J Clin Oncol* 2012; **30**: 2507.
- Niu H, Dong Z, Dong F, Zhang T, Lei T, Xue D. Experimental and clinical research of dendritic cell and syngeneic immunotherapy of brain glioma. *Chinese-German J Clin Oncol* 2004; **3**: 147-50.
- O'Rourke MGE, Johnson M, Lanagan C, et al. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. *Cancer Immunol Immunother* 2003; **52**: 387-95.
- O'Rourke MGE, Johnson MK, Lanagan CM, et al. Dendritic cell immunotherapy for stage IV melanoma. *Melanoma Res* 2007; **17**: 316-22.
- Okada H, Kalinski P, Ueda R, et al. Induction of CD8(+) T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with alpha-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid Stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. *J Clin Oncol* 2011; **29**: 330-36.
- Oosterwijk-Wakka JC, Tiemessen DM, Bleumer I, et al. Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: A phase 1 study. *J Immunother* 2002; **25**: 500-08.
- Oshita C, Takikawa M, Kume A, et al. Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial. *Oncol Rep* 2012; **28**: 1131-8.
- Palucka AK, Dhodapkar MV, Pacesny S, et al. Single injection of CD34+ progenitor-derived dendritic cell vaccine can lead to induction of T-cell immunity in patients with stage IV melanoma. *J Immunother* 2003; **26**: 432-39.
- Palucka AK, Ueno H, Connolly J, et al. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8(+) T-cell immunity. *J Immunother* 2006; **29**: 545-57.
- Pandha HS, John RJ, Hutchinson J, et al. Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study. *BJU Int* 2004; **94**: 412-18.
- Panelli MC, Wunderlich J, Jeffries J, et al. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. *J Immunother* 2000; **23**: 487-98.
- Pellegatta S, Eoli M, Frigerio S, et al. The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates. *Oncoimmunology* 2013; **2**: e23401.
- Perambakam S, Hallmeyer S, Reddy S, et al. Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide. *Cancer Immunol Immunother* 2006; **55**: 1033-42.
- Perambakam S, Xie H, Edassery S, Peace DJ. Long-term follow-up of HLA-A2+ patients with high-risk, hormone-sensitive prostate cancer vaccinated with the prostate specific antigen peptide homologue (PSA146-154). *Clin Dev Immunol* 2010; **2010**: 473453.
- Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. *Cancer Immunol Immunother* 2013; **62**: 125-35.
- Prins RM, Soto H, Konkantit V, et al. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. *Clin Cancer Res* 2011; **17**: 1603-15.
- Prins RM, Wang XY, Soto H, et al. Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients. *J Immunother* 2013; **36**: 152-57.
- Redman BG, Chang AE, Whitfield J, et al. Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma. *J Immunother* 2008; **31**: 591-98.
- Reyes D, Salazar L, Espinoza E, et al. Tumour cell lysate-loaded dendritic cell vaccine induces biochemical and memory immune response in castration-resistant prostate cancer patients. *Br J Cancer* 2013; **109**: 1488-97.
- Ribas A, Glaspy JA, Lee YH, et al. Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. *J Immunother* 2004; **27**: 354-67.
- Ribas A, Comin-Anduix B, Chmielowski B, et al. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. *Clin Cancer Res* 2009; **15**: 6267-76.
- Ribas A, Camacho LH, Lee SM, et al. Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma. *J Transl Med* 2010; **8**: 89.
- Ridolfi R, Petrini M, Fiammenghi L, et al. Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients. *J Transl Med* 2006; **4**: 36.
- Ridolfi L, Petrini M, Fiammenghi L, et al. Unexpected high response rate to traditional therapy after dendritic cell-based vaccine in advanced melanoma: update of clinical outcome and subgroup analysis. *Clin Dev Immunol* 2010; **2010**: 504979.
- Ridolfi L, Petrini M, Fiammenghi L, et al. Dendritic cell-based vaccine in advanced melanoma: update of clinical outcome. *Melanoma Res* 2011; **21**: 524-9.
- Ridolfi L, Petrini M, Granato AM, et al. Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients. *J Transl Med* 2013; **11**: 135.
- Rini BI, Weinberg V, Fong L, Conry S, Hershberg RM, Small EJ. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (Provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. *Cancer* 2006; **107**: 67-74.
- Romano E, Rossi M, Ratzinger G, et al. Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo. *Clin Cancer Res* 2011; **17**: 1984-97.
- Rutkowski S, De Vleeschouwer S, Kaempgen E, et al. Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. *Br J Cancer* 2004; **91**: 1656-62.

- Salcedo M, Bercovici N, Taylor R, et al. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. *Cancer Immunol Immunother* 2006; **55**: 819-29.
- Sampson JH, Archer GE, Mitchell DA, et al. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. *Mol Cancer Ther* 2009; **8**: 2773-79.
- Schadendorf D, Ugurel S, Schuler-Thurner B, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. *Ann Oncol* 2006; **17**: 563-70.
- Schuler-Thurner B, Dieckmann D, Keikavoussi P, et al. Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1(+) melanoma patients by mature monocyte-derived dendritic cells. *J Immunol* 2000; **165**: 3492-96.
- Schuler-Thurner B, Schultz ES, Berger TG, et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. *J Exp Med* 2002; **195**: 1279-88.
- Schwaab T, Schwarzer A, Wolf B, et al. Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN- α 2a therapy in metastatic renal cell carcinoma patients. *Clin Cancer Res* 2009; **15**: 4986-92.
- Slingsluff CL, Petroni GR, Yamshchikov GV, et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. *J Clin Oncol* 2003; **21**: 4016-26.
- Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. *J Clin Oncol* 2000; **18**: 3894-903.
- Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. *J Clin Oncol* 2006; **24**: 3089-94.
- Smithers M, O'Connell K, MacFadyen S, et al. Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen. *Cancer Immunol Immunother* 2003; **52**: 41-52.
- Steele JC, Rao A, Marsden JR, et al. Phase I/II trial of a dendritic cell vaccine transfected with DNA encoding melan A and gp100 for patients with metastatic melanoma. *Gene Ther* 2011; **18**: 584-93.
- Su Z, Dannull J, Heiser A, et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. *Cancer Res* 2003; **63**: 2127-33.
- Su Z, Dannull J, Yang BK, et al. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8(+) and CD4(+) T cell responses in patients with metastatic prostate cancer. *J Immunol* 2005; **174**: 3798-807.
- Tel J, Aarntzen EH, Baba T, et al. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. *Cancer Res* 2013; **73**: 1063-75.
- Thomas-Kaskell A-K, Zeiser R, Jochim R, et al. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival. *Int J Cancer* 2006; **119**: 2428-34.
- Thurner B, Haendle I, Roder C, et al. Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. *J Exp Med* 1999; **190**: 1669-78.
- Tjoa BA, Erickson SJ, Bowes VA, et al. Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides. *Prostate* 1997; **32**: 272-78.
- Tjoa BA, Simmons SJ, Bowes VA, et al. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. *Prostate* 1998; **36**: 39-44.
- Tjoa BA, Simmons SJ, Elgamal A, et al. Follow-up evaluation of a phase II prostate cancer vaccine trial. *Prostate* 1999; **40**: 125-29.
- Trakatelli M, Toungouz M, Blocklet D, et al. A new dendritic cell vaccine generated with interleukin-3 and interferon-beta induces CD8(+) T cell responses against NA17-A2 tumor peptide in melanoma patients. *Cancer Immunol Immunother* 2006; **55**: 469-74.
- Trefzer U, Herberth G, Wohlan K, et al. Vaccination with hybrids of tumor and dendritic cells induces tumor-specific T-cell and clinical responses in melanoma stage III and IV patients. *Int J Cancer* 2004; **110**: 730-40.
- Trepiakas R, Berntsen A, Hadrup SR, et al. Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial. *Cytotherapy* 2010; **12**: 721-34.
- Tuettenberg A, Becker C, Huter E, Knop J, Enk AH, Jonuleit H. Induction of strong and persistent MelanA/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients. *Int J Cancer* 2006; **118**: 2617-27.
- Valle RD, de Cerio AL, Inoges S, et al. Dendritic cell vaccination in glioblastoma after fluorescence-guided resection. *World J Clin Oncol* 2012; **3**: 142-9.
- Vik-Mo EO, Nyakas M, Mikkelsen BV, et al. Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. *Cancer Immunol Immunother* 2013; **62**: 1499-509.
- Vilella R, Benitez D, Mila J, et al. Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate. *Cancer Immunol Immunother* 2004; **53**: 651-58.
- von Euw EM, Barrio MM, Furman D, et al. A phase 1 clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10-1082 promoter genotype as predictor of disease progression. *J Transl Med* 2008; **6**: 6.
- Vonderheide RH, Domchek SM, Schultze JL, et al. Vaccination of cancer patients against telomerase induces functional antitumor CD8+T lymphocytes. *Clin Cancer Res* 2004; **10**: 828-39.
- Waeckerle-Men Y, Uetz-von Allmen E, Fopp M, et al. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. *Cancer Immunol Immunother* 2006; **55**: 1524-33.
- Wei YZ, Sticca RP, Holmes LM, et al. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses. *Int J Oncol* 2006; **28**: 585-93.
- Wei YC, Sticca RP, Li J, et al. Combined treatment of dendritoma vaccine and low-dose interleukin-2 in stage IV renal cell carcinoma patients induced clinical response: A pilot study. *Oncol Rep* 2007; **18**: 665-71.
- Wheeler CJ, Das A, Liu GT, Yu JS, Black KL. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. *Clin Cancer Res* 2004; **10**: 5316-26.

- Wheeler CJ, Black KL, Liu G, et al. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. *Cancer Res* 2008; **68**: 5955-64.
- Wierecky J, Muller MR, Wirths S, et al. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. *Cancer Res* 2006; **66**: 5910-18.
- Wilgenhof S, Van Nuffel AM, Corthals J, et al. Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma. *J Immunother* 2011; **34**: 448-56.
- Wilgenhof S, Van Nuffel AM, Benteyn D, et al. A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. *Ann Oncol* 2013; **24**: 2686-93.
- Yamanaka R, Abe T, Yajima N, et al. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. *Br J Cancer* 2003; **89**: 1172-79.
- Yamanaka R, Homma J, Yajima N, et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: Results of a clinical phase I/II trial. *Clin Cancer Res* 2005; **11**: 4160-67.
- Yu JS, Wheeler CJ, Zeltzer PM, et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. *Cancer Res* 2001; **61**: 842-47.
- Yu JS, Liu GT, Ying H, Yong WH, Black KL, Wheeler CJ. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. *Cancer Res* 2004; **64**: 4973-79.